Danderyd Hospital
Stockholm, Sweden
Location status: Recruiting
NCT Number: NCT04593498
The aim of the proposed study is to determine if individuals with excessive supraventricular ectopic activity (ESVEA) on Holter recording should be subjected to prolonged screening with Event loop recorder in order to detect previously undiagnosed Atrial fibrillation / flutter. Other biomarkers such as plasma biomarkers, high-end echocardiography and assessment of blood pressure and atrial stiffness will be studied and compared in ESVEA and control group as well as progression of atrial cardiomyopathy in ESVEA patients.
Interested in participating?
Request Info70 year–89 year
All sexes
Observational
Stockholm, Sweden
Location status: Recruiting
Excessive supraventricular ectopic activities (ESVEA) are a common finding on long-term ECG recordings and have a connection to atrial cardiomyopathy, incident AF, stroke and mortality.
Holter recording from 2022 preformed at Danderyd hospital will be screened in order to identify 125 recordings with ESVEA, defined as at least 30 atrial ectopic beats/hour or a supraventricular run of at least 20 consecutive beats. Participants fulfilling eligibility criteria will be offered prolonged AF screening with continuous holter recording during 14 days. A matched control group (125 participants) without ESVEA will also be screened using same method.
Cardiovascular data from medical records will be collected in order to obtain information regarding co-morbidities and being able to assess CHA2DS2-VASC score. Participants will be asked to fill in a questionnaire.
Samples of blood will be collected at index time, after 21± 3 months for further analysis with the aim of identifying biomarkers for atrial fibrillation. During these two time periods echocardiography, 24 hour ambulatory blood pressure monitoring and assessment af artery stiffness with Arteriograph will also be preformed.
The study population will after 21± 3 months be subjected to renewed screening with Holter in order to examine the persistence of excessive supraventricular activity.
Four years after the completion of screening visits, data from patient records and information thorough telephone interview and/or data from Swedish Patient Register, Swedish Dispensed Drug Register will be collected
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients with at least 30 supraventricular extra systole (SVES)/h or a supraventricular run of at least 20 beats on a Holter recording.
Exclusion criteria
Age < 70 years, >89 years Atrial fibrillation / flutter Lifelong treatment with oral anticoagulant Patients with implantable cardiac device Congestive heart failure (CHF) with Ejection fraction (EF) ≤ 30% Severe valvular heart disease
Holter recording with Zenicor Flex ECG during 14 days.
Echocardiography: Comprehensive transthoracic echocardiography with special focus on atrial dimension and function.
Blood sample: 2 x 10 ml EDTA plasma sampled from venous blood at index and at 21 months. Troponin T, NTproBNP, Na, K, Creatinine. Sample for Biobank for future analysis.
To assess artery stiffness.
Time frame: 10-14 days
Proportion of patients with at least one episode of atrial fibrillation with a duration of at least 30 seconds among patients with ESVEA on Holter recording as compared to patients without ESVEA.
Time frame: 2 years
Presence of paroxysmal or permanent atrial fibrillation on follow-up.
Time frame: 2 years
Comparison of burden of supraventricular extrasystolic beats and number of episodes and duration of longest episode of supraventricular tachycardia.
Time frame: 2 years
Explorative sequential analysis of several blood biomarkers using PEA:
Time frame: 2 years
Comparison of biomarker profile in patients diagnosed with atrial fibrillation and patients not diagnosed with atrial fibrillation.
Time frame: 4 years or longer
Long-term data on incident stroke, heart failure, major bleedning and mortality compared between ESVEA- and non-ESVEA groups.
Time frame: 2 years
Comparison of echocardiographic parameters with focus on atrial dimension and function compared between ESVEA and non-ESVEA group.
Time frame: 2 yeras
Comparison of artrial stiffness and blood pressure
Contact information is provided by the study sponsor or research team.
Karolinska Institutet
Other
Detection of Atrial Fibrillation in Patients With Excessive Supraventricular Activity
Acronym: ESA-AF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04884100
Arrhythmias, Cardiac, Atrial Fibrillation
Lausanne, Canton of Vaud, Switzerland
View Trial DetailsNCT07501299
Arrhythmia, Arrhythmias, Cardiac
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT05511389
Arrhythmias, Cardiac, Atrial Fibrillation
Hamilton, Ontario, Canada
View Trial DetailsNCT07210151
Arrhythmias, Cardiac, Atrial Arrhythmia
Split, Croatia
View Trial Details